Get started
Artofchart

Accumulate, Hold for Long term

Long
STRIDES PHARMA SCI (NSE:STAR)  
Artofchart  
NSE:STAR   STRIDES PHARMA SCI
Trend Analysis Fundamental Analysis stridespharma long-term
1
3
trendanalysis fundamental stridespharma long-term
Excellent Opportunity to buy the stock. Strides revenues in Q4FY21 grew by 47% YoY to Rs.908 cr during the quarter with sales growth in the regulated markets and emerging markets.

I have entered around the 770 mark as Investment and plan to hold for long term

Chart study, not a call
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.